Psoriasis: Which therapy for which patient

医学 银屑病 银屑病性关节炎 皮肤病科 恶性肿瘤 重症监护医学 食品药品监督管理局 生活质量(医疗保健) 疾病 内科学 药理学 护理部
作者
Shivani Kaushik,Mark Lebwohl
出处
期刊:Journal of The American Academy of Dermatology [Elsevier]
卷期号:80 (1): 27-40 被引量:274
标识
DOI:10.1016/j.jaad.2018.06.057
摘要

Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. These factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis that has led to identification of new therapeutic targets. Several new drugs have gained approval by the US Food and Drug Administration, expanding the psoriasis armamentarium, but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet the specific needs based on disease severity, the impact on quality of life, the response to previous therapies, and the presence of comorbidities. The first article in this continuing medical education series focuses on specific comorbidities and provides insights to choose appropriate systemic treatment in patients with moderate to severe psoriasis. Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. These factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis that has led to identification of new therapeutic targets. Several new drugs have gained approval by the US Food and Drug Administration, expanding the psoriasis armamentarium, but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet the specific needs based on disease severity, the impact on quality of life, the response to previous therapies, and the presence of comorbidities. The first article in this continuing medical education series focuses on specific comorbidities and provides insights to choose appropriate systemic treatment in patients with moderate to severe psoriasis. Journal Based CME Instructions and InformationJournal of the American Academy of DermatologyVol. 80Issue 1Preview Full-Text PDF CME examinationJournal of the American Academy of DermatologyVol. 80Issue 1Preview Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
大橙籽儿完成签到,获得积分10
2秒前
孤独的猕猴桃完成签到 ,获得积分10
3秒前
良辰完成签到,获得积分10
4秒前
5秒前
ohh完成签到,获得积分10
5秒前
书生也要读书完成签到,获得积分20
5秒前
Skye发布了新的文献求助10
5秒前
Polaris完成签到,获得积分10
5秒前
boluohu完成签到 ,获得积分10
6秒前
小小橙完成签到,获得积分10
7秒前
ypsun发布了新的文献求助10
7秒前
8秒前
是阿乔呢完成签到,获得积分10
8秒前
zhangrf完成签到,获得积分10
8秒前
虎咪咪完成签到,获得积分10
9秒前
隐形曼青应助吴莉采纳,获得10
10秒前
10秒前
MFNM完成签到,获得积分10
10秒前
11秒前
陈M雯完成签到,获得积分10
11秒前
12秒前
medlive2020发布了新的文献求助10
12秒前
踏实沂完成签到 ,获得积分10
13秒前
菜鸡学VASP完成签到 ,获得积分10
15秒前
15秒前
16秒前
16秒前
辛勤珠完成签到,获得积分10
17秒前
rain发布了新的文献求助10
17秒前
贺天发布了新的文献求助10
18秒前
18秒前
懦弱的乐荷完成签到,获得积分10
18秒前
19秒前
20秒前
20秒前
mikiyoo发布了新的文献求助10
20秒前
21秒前
英姑应助辛勤珠采纳,获得10
22秒前
wzy完成签到,获得积分10
22秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
薩提亞模式團體方案對青年情侶輔導效果之研究 400
3X3 Basketball: Everything You Need to Know 310
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2387865
求助须知:如何正确求助?哪些是违规求助? 2094376
关于积分的说明 5272747
捐赠科研通 1821076
什么是DOI,文献DOI怎么找? 908483
版权声明 559300
科研通“疑难数据库(出版商)”最低求助积分说明 485355